Next-Generation Probiotics

Probiotics are "live microorganisms that bestow a health benefit on the host when administered in suitable doses." Probiotics have been used safely for generations, but they were only recognised as having commercial benefit in the twentieth century. Food companies, nutritional supplement companies, and specialised probiotic manufacturing companies are expected to dominate the worldwide probiotics market, which is expected to reach a sales value of US$46.55 billion by 2020. "Next-generation probiotics" Are microorganisms that are regarded to be novel functional microbes with beneficial qualities, and the term usually refers to recently isolated bacteria. Organisms that have been developed to be utilised as living medicines to treat, cure, or diagnose disease are known as next generation probiotics (NGP) or live biotherapeutics. They are likely to be registered within a drug regulatory framework, unlike ordinary probiotics. Conventional probiotics are currently used as functional foods or supplements, whereas NGPs are primarily used as medicines, requiring a full range of registration requirements and clinical trials. Next-generation probiotics (NGPs) are one name for these organisms; however, they can also be called live biotherapeutic products (LBPs).

• Disease Ameloriation
• Postbiotics
• Optimising and Upscaling Production
• Live Biotherapeutic Products